Expert Highlights Gender/Racial Disparities in Opioid Access for Cancer Near End of Life

Video

An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.

It is “difficult” to defend the decreased access to prescription opioids some racial and ethnic minority patients with cancer face near the end of life, especially when examining access by gender, according to Andrea C. Enzinger, MD.

In an interview with CancerNetwork®, Enzinger, an assistant professor of medicine at Harvard Medical School and medical oncologist at Dana-Farber Cancer Institute, spoke about how Black men in particular were less likely to fill any end of life opioid prescriptions and long-acting opioids vs White men.

Moreover, when their prescriptions were filled, Black patients received 300 morphine milligram equivalents less than their White counterparts.

Transcript:

Coming into this study, we did expect to see disparities in access because they’ve been shown across conditions and settings such as among pediatric populations, patients with fractures, [or] for post-operative pain. What is startling to us is that this is really the emblematic population where you would hope to never see disparities among people who are dying.

There are lots of downsides to prescription opioids, and one could argue that maybe it’s a good thing that we’re not giving as many opioid pain medications in settings such as post-tooth extractions where prescribing opioids can lead to problems like substance abuse and addiction. But these are dying patients, so it’s difficult to defend any degree of disparities and especially the magnitude that we saw.

Another surprising and disconcerting finding was that we saw huge variation if you drilled down by patient characteristics beyond just race and ethnicity, particularly when you look at the interaction between patient’s gender and their race.

Black men were dramatically more affected by disparities in opioid access compared with any other group. If you look, for example, at the difference between White men and Black men in access to any prescription opioid, Black men were about 6 percentage points less likely to fill any opioid in the last month of life. They were more than 4 percentage points less likely to fill a long-acting opioid. If you look at the difference in total dose, they filled about 300 morphine milligram equivalents less than White men in the last month of life. All of the disparities were magnified substantially when you looked at Black men.

Reference

Enzinger AC, Ghosh K, Keating NL, et al. Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol. Published online January 10, 2023. doi:10.1200/JCO.22.01413

Related Videos
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.